pharmacopeia Join discussion...

Pharmacopeia to receive an initial payment in new alliance to develop novel therapeutics Pharmacopeia (NASDAQ: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, and Organon, the human healthcare business unit of Akzo Nobel (NASDAQ: AKZOY), today announced that they have entered into a new alliance to discover, develop and commercialize therapeutic products across a broad range of therapeutic indications, including neuroscience and immunology. This alliance builds on over ten years of collaborative work between Pharmacopeia and Organon. Under the terms of the alliance agreement, Pharmacopeia will receive an up-front payment of $15 million and additional payments in research funding over the five-year term of the research portion of the alliance. Join discussion...

Medarex has agreed to collaborate with Akzo Nobel's human healthcare subsidiary Organon on human antibody therapeutics research for the treatment of cancer and auto-immune disorders. Join discussion...

Medarex Summary Quote Join discussion...

edarex, Inc. (Nasdaq: MEDX) announced today that its partner MedImmune, Inc. has initiated a Phase Ib multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Join discussion...

NWBio intends to initially contribute four of its existing cancer related targets, and over the next several years, NWBio will contribute four additional, yet to be determined, cancer targets to the alliance's fully human antibody-based product development efforts. Join discussion...

Tour the new Northwest Biotherapeutic's Bothell, Washington facility during the construction process courtesy of Advanced Technology Construction Company (ATC), the Pacific Northwest's leading clean room constructors. Join discussion...